M.E. Allison & Co
GSK icon

M.E. Allison & Co’s GSK GSK Stock Holding History

M.E. Allison & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$338K Hold
7,017
– – 0.19% 135
2026
Q2 		$368K Hold
7,017
– – 0.21% 123
2026
Q1 		$387K Hold
7,017
– – 0.26% 106
2025
Q4 		$344K Sell
7,017
-1,600
-19% -$74.6K 0.23% 111
2025
Q3 		$372K Sell
8,617
-2,653
-24% -$104K 0.26% 106
2025
Q2 		$433K Buy
11,270
+484
+4% +$18.5K 0.35% 75
2025
Q1 		$418K Buy
10,786
+1,500
+16% +$54.9K 0.41% 72
2024
Q4 		$314K Buy
+9,286
New +$334K 0.35% 86

Other funds holding GSK

Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return
Sound Income Strategies
Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return
Euro Pacific Asset Management
Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return
Keystone Financial Planning
Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return
Bell Bank
Bell Bank Fargo, North Dakota $2.66B AUM 18.07% 1-Year Est. Return
Keating Investment Counselors
Keating Investment Counselors Delray Beach, Florida $382M AUM 16.71% 1-Year Est. Return
Robertson Stephens Wealth Management
Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return
Gilman Hill Asset Management
Gilman Hill Asset Management New Canaan, Connecticut $718M AUM 15.3% 1-Year Est. Return

M.E. Allison & Co's GSK Position: Q3 2026 in Review

M.E. Allison & Co held its GSK (GSK) position steady in Q3 2026 at 7,017 shares worth $338K. The position accounts for 0.19% of the portfolio, ranked #135.

M.E. Allison & Co first reported a position in GSK in Q4 2024 and has held it in 8 quarters since. The position peaked at $433K in Q2 2025. 209 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • M.E. Allison & Co held 7,017 shares of GSK worth $338K as of Q3 2026.
  • M.E. Allison & Co left its GSK share count unchanged in Q3 2026.
  • GSK made up 0.19% of M.E. Allison & Co's portfolio in Q3 2026, its #135 holding.
  • M.E. Allison & Co first reported a position in GSK in Q4 2024 and has held it in 8 quarters since.
  • M.E. Allison & Co's GSK position peaked at $433K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on M.E. Allison & Co's 13F filing for Q3 2026, filed 9 Oct 2026.